Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety
Cancer Reports · 2026
DOI: 10.1002/cnr2.70400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Nandhini Gangadaran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Dasatinib, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Leukemia, Myeloid, Chronic-Phase. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events. Emerging evidence suggests low‐dose dasatinib (50 mg daily) may maintain efficacy with improved safety, but data in imatinib‐resistant CML‐CP remain limited.
Aims
To evaluate the efficacy and safety of low‐dose dasatinib (50 mg daily) in patients with imatinib‐resistant CML‐CP and to identify predictors of treatment response and disease progression. Methods and Results This retrospective cohort study included 53 adults with imatinib‐resistant CML‐CP treated with low‐dose dasatinib at a tertiary center in Northern India (2002–2025). Early molecular response (EMR), major molecular response (MMR), deep molecular response (DMR), progression‐free survival (PFS), overall survival (OS), and adverse events were assessed. Multivariate Cox regression identified predictors of poor response and disease progression. Among 53 patients (median age 50 years), 41.5% achieved MR4.5, 20.8% MR4.0, and 15.1% MMR without DMR. Prior loss of MMR on imatinib significantly correlated with a superior response to dasatinib ( p = 0.002). TKD mutations were present in 32.1%; the T315I mutation, high ELTS risk, and baseline BCR‐ABL1 ⟩ 100% independently predicted poor response. Clinically significant adverse events occurred in 49.1%, primarily cytopenias and pleural effusion. Among our cohort, 22.6% required a TKI switch due to inadequate response and 7.5% due to intolerance.
Conclusion
Low‐dose dasatinib is effective and tolerable in imatinib‐resistant CML‐CP, with nearly two‐thirds achieving DMRs. Predictive biomarkers (T315I mutation, high ELTS risk, high baseline BCR‐ABL1) can guide dose optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
ORCID-Profile: Nandhini Gangadaran, Harshal Mamlekar, Souvik Saha, Rajesh Kashyap, Sanjeev Yadav, Khaliqur Rahman, Ruchi Gupta, Mona Vijayaran, Manish Singh, Dinesh Chandra
Zitieren
APA
Gangadaran, N., Mamlekar, H., Saha, S., Kashyap, R., Yadav, S., Rahman, K., Gupta, R., Vijayaran, M., Singh, M., & Chandra, D. (2026). Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. Cancer Reports. https://doi.org/10.1002/cnr2.70400
Vancouver
Gangadaran N, Mamlekar H, Saha S, Kashyap R, Yadav S, Rahman K, et al. Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. Cancer Reports. 2026. doi:10.1002/cnr2.70400
BibTeX
@article{Gangadaran2026,
author = {Gangadaran, Nandhini and Mamlekar, Harshal and Saha, Souvik and Kashyap, Rajesh and Yadav, Sanjeev and Rahman, Khaliqur and Gupta, Ruchi and Vijayaran, Mona and Singh, Manish and Chandra, Dinesh},
title = {Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70400}
}
EUVIMED